Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SBUX heads into its October 27 earnings date with short sellers pulling back, options traders more relaxed than usual, and the Street split between genuine optimism about the North America turnaround and concern that the recovery is fully priced.
The clearest positioning story this week is the unwinding of bearish bets. Short interest has fallen roughly 9% over the past week and around 9.5% over the past month, now sitting at 3.1% of the free float. That is a steady bleed-out from the mid-September peak near 3.8%. The borrow market offers no friction: availability is extremely loose at around 2,750%, meaning shares to borrow vastly outnumber those already lent, and cost to borrow is a negligible 0.47%. The ORTEX short score has drifted down to 38.7, continuing a gentle decline that started at the end of September from around 40.7. None of this reads as capitulation or forced covering; it looks more like a measured reduction in a position that was never particularly large. Options confirm the easing mood. The put/call ratio at 1.20 is running slightly below its 20-day average of 1.24, and at roughly half a standard deviation under that mean there is no statistical case for elevated hedging demand. Twelve months ago the ratio hit 1.45; right now it is in the quieter middle of its range.
The Street is cautiously constructive but hardly pounding the table. Most post-Q3 analyst reactions involved target increases: Wells Fargo went to $125, Evercore ISI to $120, BTIG held at $115, and a cluster of neutrals lifted their targets into the $110 to $115 range after the July results. The most recent move, JP Morgan's John Ivankoe trimming the target from $112 to $105 on September 29 while keeping Overweight, is a mild flag. It does not break the bull case but signals that execution credibility matters more than narrative from here. At $96.11 the mean target of $111.57 implies about 16% upside, a reasonable spread that keeps the stock interesting without being cheap. The forward PE has compressed about 8.6 points over the past month, landing near 26.8x. EV/EBITDA at 18.3x has also fallen roughly 2.2 turns over thirty days as the stock dropped 8%. Factor scores tell a layered story: EPS momentum over both 30 and 90 days ranks above the 90th percentile of the universe, and the dividend factor hits the 97th percentile, but value is genuinely weak with EV/EBIT in the 12th percentile, and the short score rank is a modest 43rd.
The bull and bear cases point at the same variables and reach opposite conclusions. Bulls point to the F2Q26 US comp of positive 7.1%, the 35.6 million active Rewards members, and $2 billion of cost savings flowing through into 2028 EBIT margin expansion toward 15%. Bears note that North America is more than 90% of North American segment revenue, that store operating costs are still elevated well above the 2021 to 2024 historical average at roughly 57% of sales in fiscal 2026, and that any traffic softness from the US consumer is amplified by the concentrated exposure. Both sides are essentially debating whether the Q3 comp trajectory holds into Q4 and through fiscal 2027.
One additional detail worth registering is the alt data signal: retail attention, measured by Wikipedia page views against SBUX's own 90-day history, hit a z-score of 2.96 as of September 22. That is meaningfully elevated and worth tracking into the print, though no measured relationship between Wikipedia traffic and Starbucks revenue has been established by ORTEX, so it is colour rather than a leading indicator.
The institutional register shows no activists on the 13D/G list. Capital Research and Management disclosed a 9% stake as of May, Capital World Investors filed at 8.2% as of August, and Vanguard entities collectively hold above 7%, all passive. Morgan Stanley trimmed roughly 4.8 million shares at its last report but remains above the 1% threshold. Nothing in the holder register flags urgency in either direction.
With Q4 results due October 27, the next twenty days will be about whether the same-store sales trajectory that drove the July beat has continued, and whether the margin recovery is real enough to justify even the compressed 26x PE the stock now carries.
See the live data behind this article on ORTEX.
Open SBUX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.